PCVX net incomeQ3 2026-$297.06M
PCVX net income was -$297.06M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$212.83M a year earlier. For the full fiscal 2025 it was -$766.63M, compared with -$463.93M in fiscal 2024.
Vaxcyte Inc. (PCVX) financials
For the twelve months ended Sep 30, 2026, Vaxcyte Inc. reported -$1.15B of net income.
- Net income, TTM
- -$1.15B
- Free cash flow, TTM
- -$974.42M
- EPS, diluted, TTM
- -$8.07
- Cash
- $125.47M
- Market cap
- $10.69B
FY2018FY2025
FY2018FY2025
PCVX revenue and earnings growth
PCVX EPSQ3 2026-$1.99
PCVX diluted EPS was -$1.99 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.56 a year earlier. For the full fiscal 2025 it was -$5.63, compared with -$3.80 in fiscal 2024.
PCVX free cash flowQ3 2026-$227.42M
PCVX free cash flow was -$227.42M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$147.13M a year earlier. For the full fiscal 2025 it was -$669.29M, compared with -$475.05M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $794.31M | $476.64M | $332.34M | $169.45M | $78.41M | $73.56M | $45.61M | $30.14M |
| Selling, general and admin | $129.37M | $92.90M | $60.70M | $39.81M | $25.26M | $16.02M | $8.55M | $5.39M |
| Operating income | -$923.67M | -$569.55M | -$468.04M | -$232.26M | -$103.67M | -$89.58M | -$54.15M | -$35.53M |
| Interest expense | - | $0 | $0 | $2.0K | $7.0K | $7.0K | $40.0K | $75.0K |
| Income tax | $0 | $0 | $0 | - | - | - | - | - |
| Net income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -$100.08M | -$89.22M | -$50.27M | -$29.48M |
| EPS, basic | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 | -$3.02 | -$13.25 | -$8.12 |
| EPS, diluted | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 | -$3.02 | -$13.25 | -$8.12 |
| Diluted shares | 136.1M | 122.0M | 97.2M | 64.9M | 51.9M | 29.5M | 3.8M | 3.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $173.96M | $389.19M | $397.45M | $835.53M | $69.86M | $386.20M | $58.98M | $66.09M |
| Short-term investments | $1.39B | $1.36B | $682.78M | $96.72M | $176.99M | - | - | - |
| Current assets | $1.63B | $1.79B | $1.10B | $942.55M | $256.35M | $389.00M | $61.72M | - |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.34M | $392.83M | $65.70M | - |
| Current liabilities | $205.75M | $140.18M | $145.34M | $40.52M | $28.72M | $46.86M | $11.05M | - |
| Total liabilities | $317.21M | $205.50M | $167.45M | $52.56M | $40.32M | $46.98M | $11.76M | - |
| Shareholders' equity | $2.69B | $3.31B | $1.24B | $953.61M | $284.02M | $345.84M | -$106.37M | -$57.73M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$655.58M | -$452.63M | -$296.79M | -$170.60M | -$121.39M | -$46.63M | -$47.15M | -$30.47M |
| Capital expenditures | $13.71M | $22.43M | $16.06M | $5.84M | $6.55M | $1.16M | $1.20M | $1.77M |
| Free cash flow | -$669.29M | -$475.05M | -$312.85M | -$176.44M | -$127.95M | -$47.78M | -$48.34M | -$32.24M |
| Investing cash flow | $437.35M | -$2.01B | -$773.31M | $74.58M | -$212.31M | -$1.10M | -$1.20M | -$1.77M |
| Financing cash flow | $2.01M | $2.45B | $639.81M | $861.55M | $17.80M | $374.87M | $41.57M | $62.19M |
| Stock-based compensation | $138.84M | $84.82M | $48.76M | $23.65M | $10.73M | $5.43M | $1.19M | $749.0K |
| Depreciation and amortization | $16.40M | $7.00M | $3.16M | $2.83M | $1.80M | $1.41M | $1.23M | $1.04M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -28.5% | -14.0% | -32.4% | -23.4% | -35.2% | -25.8% | - | - |
| Return on assets | -25.5% | -13.2% | -28.6% | -22.2% | -30.9% | -22.7% | -76.5% | - |
| Current ratio | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 | 8.30 | 5.58 | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $270.33M | $267.85M | $312.78M | $242.06M | $209.93M | $194.18M | $148.13M | $133.61M | $116.94M | $131.51M | $94.59M | $104.15M |
| Selling, general and admin | $37.95M | $34.92M | $33.07M | $32.22M | $32.45M | $32.04M | $32.66M | $28.55M | $22.99M | $21.47M | $19.89M | $17.53M |
| Operating income | -$308.27M | -$302.78M | -$345.85M | -$274.28M | -$242.38M | -$226.22M | -$180.79M | -$162.17M | -$139.92M | -$152.98M | -$114.47M | -$196.68M |
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$297.06M | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | -$140.72M | -$137.08M | -$103.12M | -$128.70M | -$95.02M | -$180.80M |
| EPS, basic | -$1.99 | -$1.97 | -$2.30 | -$1.81 | -$1.56 | -$1.22 | -$1.04 | -$1.02 | -$0.83 | -$1.10 | -$0.85 | -$1.83 |
| EPS, diluted | -$1.99 | -$1.97 | -$2.30 | -$1.81 | -$1.56 | -$1.22 | -$1.04 | -$1.02 | -$0.83 | -$1.10 | -$0.85 | -$1.83 |
| Diluted shares | 148.9M | 144.5M | 139.5M | - | 136.2M | 136.0M | 135.7M | - | 123.7M | 117.3M | 111.7M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $125.47M | $183.19M | $260.84M | $173.96M | $281.08M | $306.74M | $346.85M | $389.19M | $1.05B | $518.67M | $611.51M | $397.45M |
| Short-term investments | $1.17B | $1.30B | $1.48B | $1.39B | $1.43B | $1.35B | $1.32B | $1.36B | $1.13B | $934.03M | $875.01M | $682.78M |
| Current assets | $1.35B | $1.55B | $1.81B | $1.63B | $1.77B | $1.72B | $1.72B | $1.79B | $2.21B | $1.48B | $1.52B | $1.10B |
| Total assets | $2.99B | $3.14B | $3.35B | $3.00B | $3.17B | $3.31B | $3.38B | $3.51B | $3.56B | $2.09B | $2.09B | $1.41B |
| Current liabilities | $295.70M | $271.28M | $242.08M | $205.75M | $200.05M | $154.49M | $97.00M | $140.18M | $123.79M | $82.85M | $87.10M | $145.34M |
| Total liabilities | $499.92M | $380.21M | $352.29M | $317.21M | $278.72M | $234.03M | $178.08M | $205.50M | $142.11M | $101.14M | $107.32M | $167.45M |
| Shareholders' equity | $2.49B | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | $3.20B | $3.31B | $3.42B | $1.99B | $1.98B | $1.24B |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$224.08M | -$232.47M | -$280.63M | -$224.83M | -$143.31M | -$121.17M | -$166.27M | -$111.40M | -$60.71M | -$121.39M | -$159.12M | -$128.81M |
| Capital expenditures | $3.33M | $4.32M | $2.11M | $2.65M | $3.82M | $1.81M | $5.42M | $4.02M | $4.95M | $7.78M | $5.68M | $5.25M |
| Free cash flow | -$227.42M | -$236.79M | -$282.73M | -$227.49M | -$147.13M | -$122.98M | -$171.70M | -$115.42M | -$65.66M | -$129.18M | -$164.80M | -$134.06M |
| Investing cash flow | $170.77M | $147.72M | -$233.41M | $115.13M | $121.17M | $77.74M | $123.32M | -$557.17M | -$917.02M | -$80.41M | -$451.07M | -$13.93M |
| Financing cash flow | -$5.33M | $5.70M | $601.58M | $2.41M | -$3.67M | $2.52M | $759.0K | $4.91M | $1.52B | $110.37M | $818.20M | $2.73M |
| Stock-based compensation | $41.10M | $41.24M | $37.96M | $36.00M | $35.31M | $36.93M | $30.61M | $24.37M | $21.27M | $21.56M | $17.63M | $13.35M |
| Depreciation and amortization | $5.80M | $3.00M | $2.95M | $7.50M | $3.10M | $2.88M | $2.96M | $2.86M | $1.80M | $1.40M | $999.0K | $888.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.56 | 5.72 | 7.49 | 7.91 | 8.83 | 11.11 | 17.70 | 12.75 | 17.88 | 17.88 | 17.42 | 7.54 |
Source: XBRL data Vaxcyte Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PCVX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PCVX | - | - | -$1.15B | - | $10.69B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
PCVX FAQ
6 questionsIs PCVX profitable?
No. Vaxcyte Inc. reported a net loss of $1.15B for the twelve months ended Sep 30, 2026.How much cash and debt does PCVX have?
Vaxcyte Inc. reported $125.47M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PCVX free cash flow?
Vaxcyte Inc. generated -$974.42M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$962.01M less capital expenditures.What is PCVX earnings per share?
Diluted earnings per share were -$8.07 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did PCVX last report financial results?
The latest statements here come from Vaxcyte Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this PCVX financial data come from?
Quantisnow builds these statements from the structured XBRL data Vaxcyte Inc. files with the SEC. It is provided for information only and is not investment advice.